Contract HHSN272201800010I international aids vaccine initiative manufacture of influenza virus human challenge material for phase i and II clinical testing
Ended Awarded Last action
- Contract number
- 75N93023F00001
- Awardee
-
International Aids Vaccine Initiative Inc. UEI ZEJBC8JQM3P5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,625,389
Award facts
- Contract value 43% obligated
-
- $3,625,389.00 Current, with exercised options
- $8,337,685.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- New York, NY 10004, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $70,003 | |
| Exercise an Option | $2,061,379 | |
| Original award | $1,494,007 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order contract valued at $8.3 million to International AIDS Vaccine Initiative Inc. (IAVI) on September 26, 2023, for the manufacture of influenza virus human challenge material to support Phase I and II clinical testing. The contract utilizes a cost-plus-fixed-fee pricing structure and carries no set-aside designation. Work will be performed in Bowling Green, New York, with an ultimate completion date of December 31, 2025. This delivery order falls under NIAID's broader efforts to advance vaccine development and clinical trial support through manufacturing and analytical services.
IAVI, a global not-for-profit organization dedicated to developing preventive HIV vaccines and antibodies against infectious diseases, leverages its expertise in process development, cGMP manufacturing, analytical testing, and regulatory support to deliver clinical trial materials across multiple therapeutic areas. The organization maintains established relationships with NIAID through indefinite delivery/indefinite quantity contracts that enable the issuance of task orders for vaccine development services. Through this engagement, IAVI will provide the specialized manufacturing capabilities necessary to produce standardized influenza virus challenge material—a critical component for conducting controlled human infection model studies that accelerate vaccine efficacy assessment and clinical development timelines.
Quick answers
Who was awarded contract 75N93023F00001?
75N93023F00001 was awarded to International Aids Vaccine Initiative Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 26, 2023.
How much is contract 75N93023F00001 worth?
The government has obligated $3,625,389 on 75N93023F00001. Its potential value, with all options, is $8,337,685.
Is contract 75N93023F00001 an order under another contract?
Yes. 75N93023F00001 is a delivery order under 75N93018D00010, an indefinite delivery contract.
Was contract 75N93023F00001 competed?
The extent of competition for 75N93023F00001 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award